Status and phase
Conditions
Treatments
About
To study the efficacy and safety of intravenous Omegaven™ (vs. Placebo) in reducing postoperative morbidity and mortality after major liver resection.
Full description
With two single doses of Omegaven (pre- and postoperatively) we aim to reduce postoperative complications measured by the CCI (Comprehensive Complication Index) and the Clavien Dindo classification of surgical complications. The study will include adults (more than 18 years) patients requiring liver resection of at least 1 segment or multiple wedge resections (≥3).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
258 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Michael Linecker, MD; Pierre Alain Clavien, MD PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal